Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
AJR Am J Roentgenol ; 216(5): 1283-1290, 2021 05.
Article in English | MEDLINE | ID: mdl-33703926

ABSTRACT

OBJECTIVE. The purpose of this study was to identify risk factors for and outcomes of hepatotoxicity after selective chemoembolization of hepatocellular carcinoma. MATERIALS AND METHODS. This retrospective study included 182 patients (136 men and 46 women; median age, 63 years [interquartile range, 57-70 years]) who underwent 338 consecutive doxorubicin drug-eluting bead (DEB) chemoembolization procedures between 2011 and 2014. Outcomes were assessed until November 2019. In 97% of procedures, two or fewer segments were targeted. The Barcelona Clinic Liver Cancer (BCLC) stage was 0 or A for 77 procedures (22.8%), B for 75 (22.2%), C for 122 (36.1%), and D for 64 (18.9%). Hepatotoxicity was defined as worsened ascites or encephalopathy or as grade 3 or 4 elevations in liver function test results, creatinine levels, or the international normalized ratio within 30 days. Risk factors were assessed by univariate and multivariable generalized estimating equations. Transplant-free survival was assessed using Cox proportional hazard models. RESULTS. Hepatotoxicity was observed after 84 of 338 procedures (24.9%) performed for 70 of 182 patients (38.5%) and was irreversible for 40 procedures (11.8%). On multivariable analysis, risk factors for irreversible toxicity included Child-Pugh class C liver function (odds ratio [OR], 4.4; 95% CI, 1.0-19.0; p = .04), BCLC stage C (OR, 5.0; 95% CI, 1.6-16.0; p = .006) or D (OR, 7.4; 95% CI, 2.1-25.5; p = .002) disease, TIPS or hepatofugal portal venous flow (OR, 6.3; 95% CI, 2.3-17.0; p < .001), and a serum α-fetoprotein level of 200 ng/mL or greater (OR, 2.6; 95% CI, 1.1-6.1; p = .03). Irreversible toxicity was associated with reduced transplant-free survival among patients who were ineligible for liver transplant (hazard ratio, 2.5; standard error, 0.42; p = .03). CONCLUSION. Irreversible hepatotoxicity was common after selective chemoembolization in patients with advanced stage disease, an elevated serum α-fetoprotein level, or reduced hepatic portal venous perfusion, and it may hasten death among patients who are ineligible for liver transplant.


Subject(s)
Carcinoma, Hepatocellular/therapy , Chemical and Drug Induced Liver Injury/mortality , Chemoembolization, Therapeutic/adverse effects , Chemoembolization, Therapeutic/mortality , Liver Neoplasms/therapy , Aged , Carcinoma, Hepatocellular/mortality , Chemoembolization, Therapeutic/methods , Cohort Studies , Female , Humans , Liver Neoplasms/mortality , Male , Middle Aged , Retrospective Studies , San Francisco/epidemiology , Survival Analysis , Treatment Outcome
2.
Am J Surg ; 222(1): 234-240, 2021 07.
Article in English | MEDLINE | ID: mdl-33384155

ABSTRACT

BACKGROUND: Opioids are generally discouraged and used sparingly in liver transplant (LT) candidates prior to LT. This study examined the relationship between opioid use at the time of LT and graft and patient survival following transplantation. METHODS: A retrospective single center cohort study of LT recipients from June 2012 to December 2019 was performed. Primary outcomes were graft and patient survival, analyzed with the Kaplan-Meier method and Cox proportional hazards models; primary predictor was active opioid prescription at LT. RESULTS: 751 LT recipients were included; 16% had an opioid prescription at LT. Post-transplant death was significantly greater in opioid users (pvalue<0.001). In a multivariable Cox model examining predictors of death, opioid use remained associated with a significant increase in the risk of death (HR 2.4 CI 1.5-4.0, p < 0.001) even after controlling for other factors. CONCLUSION: Opioid use at LT is associated with a markedly increased risk of death following transplant.


Subject(s)
Analgesics, Opioid/therapeutic use , End Stage Liver Disease/surgery , Graft Rejection/epidemiology , Liver Transplantation/adverse effects , Pain/drug therapy , Aged , Drug Prescriptions/statistics & numerical data , End Stage Liver Disease/complications , End Stage Liver Disease/diagnosis , End Stage Liver Disease/mortality , Female , Graft Rejection/etiology , Graft Survival , Humans , Kaplan-Meier Estimate , Liver Transplantation/standards , Male , Middle Aged , Pain/diagnosis , Pain/epidemiology , Pain/etiology , Retrospective Studies , Risk Assessment/statistics & numerical data , Risk Factors , Severity of Illness Index , Transplant Recipients/statistics & numerical data , United States/epidemiology
5.
Hepatol Commun ; 1(1): 18-22, 2017 02.
Article in English | MEDLINE | ID: mdl-29404430

ABSTRACT

While there are guidelines from all major liver societies for the screening and management of hepatocellular carcinoma (HCC), many issues remain surrounding the actual practice of screening. This review discusses how to diagnose and screen HCC and more importantly, how well we diagnose and screen for HCC. Improved survival and outcomes after HCC diagnosis depend upon accurate diagnosis of cirrhosis and the timeliness of screening. With all oral direct-acting antivirals now widely available for hepatitis C, there are increasing numbers of patients who may be cured but are still at risk of HCC. Some uncontrolled studies suggest that direct-acting antiviral therapy may even increase the risk of HCC. Before we discuss expansion of who should be screened, we need physicians to realize how poorly we screen those patients who are already recommended for screening by guidelines. (Hepatology Communications 2017;1:18-22).

SELECTION OF CITATIONS
SEARCH DETAIL
...